Weight Gain on Contemporary Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide in Persons With HIV Starting Antiretroviral Therapy in the United States and Canada
The Journal of Infectious Diseases · 23.09.2026 · 234 (3) · 352-360
DOI: 10.1093/infdis/jiag271 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 29.05.2026. Verfasst von Kassem Bourgi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Nashville CARES, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: HIV Infections, Tenofovir, Weight Gain, Adenine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS, National Institute for Mental Health.
Abstract (Originalsprache)
Background
Weight gain is common following antiretroviral therapy (ART) initiation. Integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF) have been associated with greater weight gain, though prior analyses may have been confounded by the weight-suppressive effects of efavirenz (EFV) and tenofovir disoproxil fumarate (TDF).
Methods
Treatment-naive adults in the North American AIDS Cohort Collaboration on Research and Design initiating ART between 2007 and 2021 were analyzed. Predicted weight change was modeled using linear mixed effects models adjusted for demographic and clinical factors, and nucleoside reverse transcriptase inhibitor (NRTI) backbone, with subanalyses excluding EFV and stratifying by INSTI agent, NRTI, sex, and race.
Results
A total of 32 514 persons were included. At 2 years, INSTIs (4.9 kg, 95% CI: 4.6–5.2) and protease inhibitors (PIs) (4.7 kg, 95% CI: 4.4–5.1) were associated with greater mean predicted weight gain compared to non-nucleoside reverse transcriptase inhibitors (NNRTIs) (2.7 kg, 95% CI: 2.4–2.9). Differences persisted when limiting analyses to TDF-containing regimens and excluding EFV. Among INSTIs, mean predicted weight gain was numerically highest with bictegravir (6.9 kg, 95% CI: 5.8–7.9), followed by dolutegravir (5.3 kg, 95% CI: 4.8–5.9), raltegravir (4.5 kg, 95% CI: 3.8–5.3), and elvitegravir (4.0 kg, 95% CI: 3.6–4.5). Participants receiving TAF with INSTIs gained more than those on TDF. Black females on bictegravir or dolutegravir with TAF had the highest gain at 2 years (10.0 kg, 95% CI: 7.4–12.6)
Conclusions
Weight gain with non-EFV NNRTIs was lower than with PIs and INSTIs, with the greatest increases observed among Black females starting TAF with contemporary INSTIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nashville CARES, Nashville, Tennessee, USA.
- Department of Medicine, Indiana University, Indianapolis, Indiana, USA.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Gilead Sciences, Foster City, California, USA.
- Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
- Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
ORCID-Profile: Kassem Bourgi, Lakeisha Boyd, Samir K Gupta, Jean C Lee, Timothy R Sterling, Richard D Moore, Catherine Lesko, Jordan E Lake, George A Yendewa, Michael J Silverberg, Keri Althoff, Joseph Margolick, Peter F Rebeiro, John R Koethe
Förderung
- NIH HHS
- NIAID NIH HHS
- National Institute for Mental Health
- NIA NIH HHS
- NHLBI NIH HHS
- NIDCD NIH HHS
- NIDCR NIH HHS
- NINR NIH HHS
Zitieren
APA
Bourgi, K., Bian, A., Boyd, L., Gupta, S. K., Cohen, C., Lee, J. C., Sterling, T. R., Moore, R. D., Lesko, C., Lake, J. E., Yendewa, G. A., Horberg, M. A., Silverberg, M. J., Palella, F. J., Althoff, K., Margolick, J., Rebeiro, P. F., Koethe, J. R., & North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) (2026). Weight Gain on Contemporary Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide in Persons With HIV Starting Antiretroviral Therapy in the United States and Canada. The Journal of Infectious Diseases, 234(3), 352-360. https://doi.org/10.1093/infdis/jiag271
Vancouver
Bourgi K, Bian A, Boyd L, Gupta SK, Cohen C, Lee JC, et al. Weight Gain on Contemporary Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide in Persons With HIV Starting Antiretroviral Therapy in the United States and Canada. The Journal of Infectious Diseases. 2026;234(3):352-360. doi:10.1093/infdis/jiag271
BibTeX
@article{Bourgi2026,
author = {Bourgi, Kassem and Bian, Aihua and Boyd, Lakeisha and Gupta, Samir K and Cohen, Cal and Lee, Jean C and Sterling, Timothy R and Moore, Richard D and Lesko, Catherine and Lake, Jordan E and Yendewa, George A and Horberg, Michael A and Silverberg, Michael J and Palella, Frank J and Althoff, Keri and Margolick, Joseph and Rebeiro, Peter F and Koethe, John R and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)},
title = {Weight Gain on Contemporary Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide in Persons With HIV Starting Antiretroviral Therapy in the United States and Canada},
journal = {The Journal of Infectious Diseases},
year = {2026},
volume = {234},
number = {3},
pages = {352--360},
doi = {10.1093/infdis/jiag271}
}
EUVIMED